Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined molecular subclass and immune phenotype correlate to atezolizumab plus radiation therapy response in invasive bladder cancer: BPT-ART Phase II study.
Nagumo Y, Hattori K, Kimura T, Sekino Y, Naiki T, Kobayashi Y, Matsumoto T, Osawa T, Kita Y, Takemura M, Mathis BJ, Suzuki S, Tsuzuki T, Ishikawa H, Nishiyama H. Nagumo Y, et al. Int J Radiat Oncol Biol Phys. 2025 Jan 2:S0360-3016(24)03774-X. doi: 10.1016/j.ijrobp.2024.12.019. Online ahead of print. Int J Radiat Oncol Biol Phys. 2025. PMID: 39755215
The correlation between discrepancies in clinical and pathological T stages and overall survival in upper urinary tract urothelial carcinoma: Analysis of the hospital-based cancer registry data in Japan.
Shiga M, Nagumo Y, Kojo K, Kandori S, Takahashi R, Isoda B, Suzuki S, Hamada K, Tanuma K, Nitta S, Hoshi A, Negoro H, Mathis BJ, Okuyama A, Nishiyama H. Shiga M, et al. Among authors: nagumo y. Int J Urol. 2025 Jan 3. doi: 10.1111/iju.15665. Online ahead of print. Int J Urol. 2025. PMID: 39749844
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.
Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group. Tanegashima T, et al. Among authors: nagumo y. Int J Clin Oncol. 2024 Dec 17. doi: 10.1007/s10147-024-02681-2. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39688742
Variations in the diagnostic performance of transurethral resection of bladder tumor with photodynamic diagnosis according to surgical experience: A retrospective, single-center study.
Suzuki S, Nagumo Y, Kojo K, Ikeda A, Isoda B, Yamaguchi A, Tanuma K, Nitta S, Shiga M, Kawahara T, Kandori S, Hoshi A, Negoro H, Mathis BJ, Nishiyama H. Suzuki S, et al. Among authors: nagumo y. Photodiagnosis Photodyn Ther. 2024 Dec 3;51:104429. doi: 10.1016/j.pdpdt.2024.104429. Online ahead of print. Photodiagnosis Photodyn Ther. 2024. PMID: 39638220 Free article.
Maediastinal germ cell tumors: analysis using hospital-based cancer registry data in Japan.
Takahashi R, Nitta S, Kandori S, Suzuki S, Hamada K, Tanuma K, Kojo K, Shiga M, Sakka S, Nagumo Y, Mathis BJ, Hoshi A, Negoro H, Okuyama A, Higashi T, Nishiyama H. Takahashi R, et al. Among authors: nagumo y. Int J Clin Oncol. 2024 Nov;29(11):1756-1761. doi: 10.1007/s10147-024-02607-y. Epub 2024 Sep 5. Int J Clin Oncol. 2024. PMID: 39235705
TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab.
Isoda B, Kandori S, Sazuka T, Kojima T, Nitta S, Shiga M, Nagumo Y, Fujimoto A, Arai T, Sato H, Mathis BJ, Wu CL, Jan YH, Ichikawa T, Nishiyama H. Isoda B, et al. Among authors: nagumo y. Int J Mol Sci. 2024 Jul 6;25(13):7444. doi: 10.3390/ijms25137444. Int J Mol Sci. 2024. PMID: 39000552 Free PMC article.
178 results